Comparative Pharmacology
Head-to-head clinical analysis: CLARAVIS versus ISOTRETINOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARAVIS versus ISOTRETINOIN.
CLARAVIS vs ISOTRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isotretinoin, a retinoid, reduces sebum production, inhibits sebaceous gland activity, and normalizes follicular keratinization. It also exhibits anti-inflammatory effects.
Reduces sebum production, inhibits sebaceous gland activity, and induces apoptosis in sebocytes. Binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) to regulate gene expression.
Oral: 30 mg once daily after a meal for 12 weeks; administration with high-fat meal increases absorption.
0.5-1 mg/kg/day orally in two divided doses for 15-20 weeks; cumulative dose 120-150 mg/kg.
None Documented
None Documented
Terminal half-life: 19-24 hours in adults; prolonged in renal impairment (up to 50 hours in ESRD).
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life is approximately 20 hours (range 10-30 hours) for the parent drug. Clinical significance: steady-state achieved in ~5 days with repeated dosing; prolongation in renal impairment is minimal.
Renal: 90% as unchanged drug; fecal: 5%; biliary: <1%.
Primarily hepatic metabolism; metabolites excreted in urine (65-80%) and feces (15-35%). Less than 1% excreted unchanged in urine.
Category C
Category D/X
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."